Penumbra Inc Stock News

ALAMEDA, Calif. , May 1, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the RBC Capital Markets Global Healthcare Conference on Wed

Penumbra's (PEN) latest offering is likely to enable physicians to restore blood flow more quickly and further minimize blood loss.

Investors with an interest in Medical - Instruments stocks have likely encountered both Globus Medical (GMED) and Penumbra (PEN). But which of these two companies is the best option for those looking

Investors are optimistic about Penumbra (PEN) on strength exhibited in the Thrombectomy business and global expansion.

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Penumbra (PEN) expects to materially increase both revenues and profitability in the company's international business in the next three years and beyond.

Penumbra's (PEN) Q4 revenues register year-over-year growth driven by robust U.S. thrombectomy sales.

Penumbra (PEN) came out with quarterly earnings of $0.76 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.16 per share a year ago.

Investors remain optimistic for Penumbra (PEN), backed by the strength of its portfolio.

Stocks like DexCom Inc. (DXCM), Integer Holdings (ITGR), Penumbra (PEN), Haemonetics (HAE), Health Equity (HAE) and are likely to continue their strong performance in 2024.

Investors are optimistic about Penumbra (PEN), driven by growth in the vascular segments and upbeat guidance.

Investors are optimistic about Penumbra (PEN), which is led by growth in vascular and neuro businesses.

ALAMEDA, Calif. , Dec. 18, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the J.P.

Penumbra (PEN) achieves an important milestone by enrolling the first patient in STORM-PE RCT.

Investors are optimistic about Penumbra (PEN) on strong vascular and neuro businesses growth and upbeat guidance.